Antibodies News and Research

RSS

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world.

9 Jul 2021

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

However, it cannot be confirmed for certain that the strain has been eliminated, raising the question of how long a strain must go undetected before being considered, in all probability, extinct.

9 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Why is the SARS-CoV-2 Delta variant so concerning?

As cases surge in the United States, health experts have raised the alarm that vaccinated individuals may be spreading the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant. Over half of new infections in the U.S. are now caused by this highly transmissible variant.

9 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Researchers in the United States have identified both antigen-specific and antigen non-specific predictive signatures of antibody responses to Moderna’s two-dose coronavirus disease 2019 (COVID-19) vaccine that protects against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

Intranasal COVID-19 vaccine protects animals against lethal COVID-19 infection

In a new study assessing the potential of a single-dose, intranasal COVID-19 vaccine, a team from the University of Iowa and the University of Georgia found that the vaccine fully protects mice against lethal COVID-19 infection.

8 Jul 2021

Genetic analysis method reveals causal association between thyroid function and serum lipid metabolism

Thyroid hormones are amino acid-based molecules produced by the thyroid gland. Involved in direct or indirect regulation of key metabolic pathways, these molecules play critical roles in the development and normal functioning of the body.

8 Jul 2021

New AI systems offers quicker, more accurate diagnosis for blistering disease

Scientists at the University of Groningen have trained an Artificial Intelligence system to recognize a specific pattern in skin biopsies of patients with the blistering disease epidermolysis bullosa acquisita.

8 Jul 2021

Growing concern over SARS-CoV-2 Lambda variant

A new report from Chile – currently available on the medRxiv* preprint server – reveals how mutations in the spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Lambda variant can confer protection from neutralizing antibodies and increase viral infectivity rates, which means massive vaccination campaigns should be accompanied by strict genomic surveillance.

8 Jul 2021

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Researchers in Germany have provided evidence that a booster shot of a messenger RNA (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine following prime immunization with AstraZeneca’s adenoviral vector-based vaccine is sufficient to achieve high levels of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2021

Changes to COVID-19 vaccination strategy could speed up herd immunity

Researchers in the United States have proposed changes to the current coronavirus disease 2019 (COVID-19) vaccination strategy that they say would increase the likelihood of herd immunity being achieved in the most timely and cost-effective manner.

8 Jul 2021

Scientists study how our immune system responds to COVID-19 variants

Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not as effective against contemporary variants of the virus.

8 Jul 2021

Researchers discover how to artificially produce healthy mucus

Many people instinctively associate mucus with something disgusting, but in fact, it has incredibly many valuable functions for our health. It keeps track of our important intestinal flora and feeds the bacteria.

8 Jul 2021

New biological pathway selectively controls how key immune cells mature into functional components

Immunologists at St. Jude Children's Research Hospital have identified a biological pathway that selectively controls how key immune cells, called T follicular helper cells, mature into functional components of the immune system.

8 Jul 2021

How SARS-CoV-2 has evolved over the course of the pandemic

In an effort to understand the ongoing evolution of the SARS-CoV-2 genome, researchers constructed a phylogenetic tree of all available SARS-CoV-2 genomes.

7 Jul 2021

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

A new paper discusses an intriguing new mechanism of immune evasion traceable to specific mutations in the B.1.427/B.1.429 variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

7 Jul 2021

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2

QUT PhD researcher Zachariah Schuurs said the research team had identified a new binding site on the SARS-CoV-2 spike protein.

7 Jul 2021

Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens

A McMaster University team of researchers recently discovered how, exactly, the COVID-19 vaccines that use adenovirus vectors trigger a rare but sometimes fatal blood clotting reaction called vaccine-induced immune thrombotic thrombocytopenia or VITT.

7 Jul 2021

Antibodies News and Research

Scientists analyze the sensitivity of SARS-CoV-2 Delta variant to monoclonal antibodies

Researchers model probability of extinction of SARS-CoV-2 variant in an outbreak

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Why is the SARS-CoV-2 Delta variant so concerning?

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Early B cell signatures predict antibody responses to mRNA-based COVID-19 vaccine

Intranasal COVID-19 vaccine protects animals against lethal COVID-19 infection

Genetic analysis method reveals causal association between thyroid function and serum lipid metabolism

New AI systems offers quicker, more accurate diagnosis for blistering disease

Growing concern over SARS-CoV-2 Lambda variant

Striking increase in SARS-CoV-2 antibodies seen with prime dose AstraZeneca vaccine followed by Pfizer-BioNTech

Changes to COVID-19 vaccination strategy could speed up herd immunity

Scientists study how our immune system responds to COVID-19 variants

Researchers discover how to artificially produce healthy mucus

New biological pathway selectively controls how key immune cells mature into functional components

How SARS-CoV-2 has evolved over the course of the pandemic

B.1.427/B.1.429 variant of SARS-CoV-2 evades neutralization via disulfide bond rearrangement

Common anti-coagulant drug could treat emerging variants of SARS-CoV-2

Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo